IMA Stock Forecast & Price Target

ImageneBio is compelling because its lead asset IMG-007 targets the clinically validated OX40-OX40L axis while improving on earlier agents through a non-depleting, Fc-silent design, roughly five-week half-life, and no measurable ADCC, which could translate into better safety, durability, and less frequent dosing. The investment case is reinforced by proof-of-concept in atopic dermatitis, where three IV doses produced an 87% mean EASI reduction through Week 20, and by alopecia areata data showing a 21.7% mean SALT improvement at Week 36 in 29 patients, supporting a second indication with meaningful upside. Financially, the company had $136M of cash at the end of 2Q26, no revenue in 2Q26, a projected first risk-adjusted product revenue of $33M in 2032, and potential risk-adjusted revenue of $867M by 2037, which appears attractive relative to its current negative enterprise value of about $(40)M.

ImageneBio is viewed negatively because its flagship IMG-007 program continues to face meaningful execution risk, with a protocol amendment in Ph 2 ADAPTIVE and topline data now guided for 4Q27, later than an earlier 4Q26 estimate. The analyst remains skeptical that enrollment will progress quickly in the OX40/OX40L class, and the delay raises concern about the company’s operational runway even if IMG-007 ultimately shows a better safety profile than amlitelimab and rocatinlimab. Fundamentally, the outlook is pressured by dependence on a single clinical asset, while valuation assumptions already rely on 2035-37E worldwide sales and a discounted sum-of-parts framework, underscoring how far-dated and uncertain the thesis remains.